Acute effects of intratracheal administration of platelet-activating factor in baboons.
The bronchomotor effect of intratracheal administration of PAF-acether (60 micrograms X kg -1) was investigated in 37 curarized baboons mechanically ventilated with constant volume and frequency. PAF-acether caused an immediate bronchoconstriction as assessed by a marked increase in peak inspiratory pressure with no change in static pulmonary compliance and chest X-rays. There was a concomitant fall in arterial PO2 and a significant increase in ventilated unperfused lung zones. A decrease of circulating platelets and leucocytes was also observed. Local anesthesia with lidocaine and atropine did not prevent PAF-acether-induced bronchoconstriction although both markedly reduced the bronchial response to histamine. Albuterol significantly reduced the bronchial response to PAF-acether. Pretreatment with aspirin (80 mg X kg -1 iv) did not prevent the bronchoconstriction caused by PAF-acether, and intravenous or intratracheal arachidonic acid caused no bronchial response. Thus the role of cyclooxygenase metabolites of arachidonic acid in PAF-acether-induced bronchoconstriction is unlikely. In conclusion, an acute bronchoconstriction probably not triggered by stimulation of irritant receptors of the airways and associated with aggregation of platelet takes place subsequent to intratracheal administration of PAF-acether. These data suggest that PAF-acether might play a role in the pathogenesis of human asthma.
D000772:Anesthesia, Local; D000818:Animals; D001241:Aspirin / Q000494:pharmacology; D001285:Atropine / Q000494:pharmacology; D001980:Bronchi / Q000276:immunology; D001986:Bronchial Spasm / Q000276:immunology; D008012:Lidocaine; D010215:Papio / Q000502:physiology*; D010972:Platelet Activating Factor / Q000008:administration & dosage* / Q000276:immunology; D013997:Time Factors; D014132:Trachea
D010972:Platelet Activating Factor; D001285:Atropine; D008012:Lidocaine; D001241:Aspirin